Kaptein, Suzanne J F; Goethals, Olivia; Kiemel, Dominik; Marchand, Arnaud; Kesteleyn, Bart; Bonfanti, Jean-Francois; Bardiot, Dorothee; Stoops, Bart; Jonckers, Tim H M; Dallmeier, Kei; Geluykens, Peggy; Thys, Kim; Crabbe, Marjolein; Chatel-Chaix, Laurent 
ORCID: https://orcid.org/0000-0002-7390-8250; Münster, May; Querat, Gilles; Touret, Franck; de Lamballerie, Xavier; Raboisson, Pierre; Simmen, Kenny; Chaltin, Patrick; Bartenschlager, Ralf; Van Loock, Marnix et Neyts, Johan
(2021).
A pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction
Nature
, vol. 598
, nº 7881.
pp. 504-509.
DOI: 10.1038/s41586-021-03990-6.
Résumé
Dengue virus causes approximately 96 million symptomatic infections annually, manifesting as dengue fever or occasionally as severe dengue(1,2). There are no antiviral agents available to prevent or treat dengue. Here, we describe a highly potent dengue virus inhibitor (JNJ-A07) that exerts nanomolar to picomolar activity against a panel of 21 clinical isolates that represent the natural genetic diversity of known genotypes and serotypes. The molecule has a high barrier to resistance and prevents the formation of the viral replication complex by blocking the interaction between two viral proteins (NS3 and NS4B), thus revealing a previously undescribed mechanism of antiviral action. JNJ-A07 has a favourable pharmacokinetic profile that results in outstanding efficacy against dengue virus infection in mouse infection models. Delaying start of treatment until peak viraemia results in a rapid and significant reduction in viral load. An analogue is currently in further development.
| Type de document: | Article |
|---|---|
| Mots-clés libres: | - |
| Centre: | Centre INRS-Institut Armand Frappier |
| Date de dépôt: | 30 juin 2022 13:57 |
| Dernière modification: | 30 juin 2022 13:57 |
| URI: | https://espace.inrs.ca/id/eprint/12360 |
Gestion Actions (Identification requise)
 |
Modifier la notice |